Beth Hecht - 20 Mar 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chief Legal Officer and Corporate Secretary
Signature
/s/ Beth Hecht
Issuer symbol
XERS
Transactions as of
20 Mar 2025
Net transactions value
-$217,244
Form type
4
Filing time
21 Mar 2025, 17:31:00 UTC
Previous filing
03 Feb 2025
Next filing
13 Nov 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Sale $217,244 -40,000 -2.9% $5.43 1,353,510 20 Mar 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.380 to $5.475, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

Chief Legal Officer and Corporate Secretary